Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Nokia Corp (NOK) Price & Performance

Neurocrine Biosciences IncTrade
Nokia CorpTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Nokia Corp — how do they compare? Neurocrine Biosciences Inc trades at $157.8 (market cap $16.46B), while Nokia Corp trades at $10.37 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and Nokia Corp pays a 1.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXNOK
Market Cap
$16.46B$53.00B
Sector
HealthTechnology
52-Week High
$185.50$16.83
52-Week Low
$123.10$4.13
Enterprise Value
$16.48B$50.95B
Dividend Yield
1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Nokia Corp

Nokia (NOK) trades at $10.375, up 13.76% today, reflecting strong momentum amid AI infrastructure demand. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, Q2 2026 earnings beat profit estimates, driven by AI and cloud growth, though revenue missed. Analyst sentiment is bullish with 60% buy ratings, while cash flow trends indicate volatility with a net outflow of $1.16B in 2025.

The outlook is cautiously optimistic, with AI-driven demand offsetting telecom challenges. Key opportunities include expanding AI networking and cloud infrastructure, but risks involve uneven telecom spending and competitive pressures. Investors should weigh strong analyst support against cash flow instability and margin pressures for balanced exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK